ISPE CEO to Step Down at End of 2014 - - BioPharm International

ADVERTISEMENT

ISPE CEO to Step Down at End of 2014


The International Society for Pharmaceutical Engineering (ISPE) has announced that CEO Nancy Berg will leave the Society when her three-year contract is completed at the end of 2014.

During her tenure with ISPE, Berg was responsible for the world’s largest professional society fostering dialog and education on technical, scientific, and regulatory best practices in the pharmaceutical and biotech industries. In a press statement, ISPE identified Berg as the architect of the Society’s ongoing strategic plan, focusing on initiatives related to drug shortages, quality metrics, global manufacturing quality, facility and supply chain issues, and patient experiences in clinical trials. She worked to create synergies between pharmaceutical industry stakeholders, bringing together diverse groups of professionals, regulators, and partner organizations to work on issues of shared concern.

Under Berg’s leadership, ISPE introduced a strategic redirection of focus in Europe and Asia, plans to establish a Washington, DC office in 2014 an office in Washington, DC, and launched the Pharma EXPO tradeshow (3 – 5 November 2014, Chicago), in partnership with PMMI.

Working through the end of 2014, Berg will continue to strengthen the organization, support the Board of Directors as it identifies a new CEO, and establish ISPE’s Washington office, the statement says.

 “ISPE appreciates the strategic and directional work contributed by Nancy Berg. Her efforts have established an essential foundation for ensuring ISPE is a dynamic and relevant driver of value for its Members and the pharmaceutical industry,” says Damian Greene, 2014 Chair of ISPE’s International Board of Directors and Global Network Strategy Lead, Global Manufacturing and Supply at Zoetis, Brussels, Belgium.

The search for ISPE’s CEO is being conducted by Pamela Kaul, president, Association Strategies, Inc.

Source: ISPE

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here